评估肾细胞癌临床试验机会的全球差异.pdf

1、Evaluating Global Disparities in Clinical Trial Availability for Renal Cell CarcinomaRuchi Agarwal1*,J.Goud2*,M.Zugman2,D.Castro2,X.Li2,K.Shah2,L.Lau2,A.Lee2,S.Jaime-Casas2,H.Ebrahimi2,G.Regalado-Porras3,S.Choi4,N.Sobrevilla-Moreno5,E.Ruiz-Garcia5,S.Kooner2,S.Reid2,N.Chaudhary2,R.McKay4,S.Pal2,and R

2、.Barragan-Carrillo2,51 University of Pennsylvania,Philadelphia,PA,USA 2 City of Hope Comprehensive Cancer Center,Duarte,CA,USA3 ABC Medical Center,Mexico City,MX4 University of California San Diego,La Jolla,CA,USA5 National Cancer Institute of Mexico,Mexico City,MX*Equal contribution Background:Clin

3、ical trials are key to generating high-quality evidence to improve patient outcomes.In metastatic renal cell carcinoma,research over the past two decades has resulted in a fourfold increase in median overall survival(Lancet,2024).Most trials are conducted in high-income countries(HICs),limiting the

4、inclusion of diverse patient populations(JCO CCI,2020).Aim:To assess the global distribution of renal cell carcinoma(RCC)clinical trials and identify disparities by country income level.Methodology:EXCLUSION ZONE Queried the National Clinical Trials database for RCC trials enrolling patients between

5、 June 2019 and June 2024,excluding non-interventional,pediatric,and non-RCC trials.Countries were categorized by World Bank Ranking(WBR):high-income countries(HICs),upper-middle-income countries(UMICs),lower-middle-income countries(LMICs),and low-income countries(LICs).Analyses included:Descriptive

6、statistics for trial characteristics(e.g.,histology,phase,stage,etc.)Kruskal-Wallis test for differences by income level Poisson regression to assess links with income,gross national income(GNI),health spending,and RCC burdenResults:A total of 357 eligible trials were identified.Most(N=273;76%)were